19 days ago
HROW
AnalystsMayank MamtaniMayank Mamtani's Stock Forecasts
AnalystsMayank Mamtani
Analyst Ranking
Top 4%
#154 out of 5069 analysts
Average Return
+33.5%
Win Rate
45%60 out of 134
Risk vs Reward
Poor
Good
Mayank Mamtani's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Novavax IncNVAX | +1,295.56% | $13.05 | $182.12 | 2020-03-27 - 2021-03-26 | Strong Buy |
Novavax IncNVAX | +946.95% | $19.83 | $207.61 | 2020-04-24 - 2021-04-23 | Strong Buy |
Tg Therapeutics IncTGTX | +534.38% | $4.13 | $26.20 | 2022-06-13 - 2023-06-12 | Strong Buy |
Cymabay Therapeutics IncCBAY | +382.37% | $1.90 | $9.17 | 2022-05-18 - 2023-05-17 | Strong Buy |
Trevi Therapeutics IncTRVI | +245.49% | $2.88 | $9.95 | 2024-10-07 - 2025-10-06 | Strong Buy |
Mayank Mamtani Analyst Color
Get additional color on Mayank Mamtani's coverage of popular stocks
21 days ago
MDGL
a month ago
CYTK
a month ago
TGTX
a month ago
TBPH
6 months ago
MDGL
7 months ago
TRVI
10 months ago
CGTX
a year ago
NVAX
a year ago
NVAX
2 years ago
TGTX
2 years ago
CBAY
3 years ago
NVAX
3 years ago
CKPT
3 years ago
ALT
Mayank Mamtani's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Zymeworks IncZYME | 1 | Strong Buy | $30.00 | +63.04% | Initiates Coverage On | 10 days ago |
Harrow IncHROW | 4 | Strong Buy | $74.00 | +84.95% | Reiterates | 19 days ago |
Madrigal Pharmaceuticals IncMDGL | 10 | Strong Buy | $560.00 | +27.59% | Maintains | 21 days ago |
Nektar TherapeuticsNKTR | 3 | Strong Buy | $105.00 | +81.76% | Maintains | a month ago |
Cytokinetics IncCYTK | 4 | Strong Buy | $80.00 | +36.89% | Maintains | a month ago |
Tg Therapeutics IncTGTX | 12 | Strong Buy | $55.00 | +58.64% | Maintains | a month ago |
Theravance Biopharma IncTBPH | 1 | Strong Buy | $28.00 | +96.35% | Initiates Coverage On | a month ago |
Actuate Therapeutics IncACTU | 1 | Strong Buy | $20.00 | +167.38% | Initiates Coverage On | 2 months ago |
Altimmune IncALT | 9 | Strong Buy | $18.00 | +369.97% | Maintains | 2 months ago |
Medicinova IncMNOV | 2 | Strong Buy | $5.00 | +306.50% | Maintains | 4 months ago |
Macrogenics IncMGNX | 2 | Hold | $3.00 | +81.82% | Maintains | 5 months ago |
Vaxart IncVXRT | 5 | Strong Buy | $2.00 | +525.00% | Maintains | 7 months ago |
Trevi Therapeutics IncTRVI | 3 | Strong Buy | $20.00 | +93.05% | Reiterates | 7 months ago |
Lineage Cell Therapeutics IncLCTX | 2 | Strong Buy | $3.00 | +81.82% | Maintains | 7 months ago |
Denali Therapeutics IncDNLI | 2 | Strong Buy | $35.00 | +110.08% | Reiterates | 8 months ago |
Arrowhead Pharmaceuticals IncARWR | 7 | Strong Buy | $38.00 | +3.23% | Reiterates | 8 months ago |
Viking Therapeutics IncVKTX | 2 | Strong Buy | $96.00 | +186.27% | Reiterates | 8 months ago |
Cognition Therapeutics IncCGTX | 3 | Strong Buy | $1.50 | -13.79% | Upgrades | 10 months ago |
Novavax IncNVAX | 16 | Strong Buy | $26.00 | N/A | Reiterates | a year ago |
Gritstone Bio IncGRTSQ | 4 | Hold | $1.00 | N/A | Downgrades | a year ago |
Centessa Pharmaceuticals PLCCNTA | 1 | Strong Buy | $33.00 | N/A | Initiates Coverage On | a year ago |
Cymabay Therapeutics IncCBAY | 5 | Hold | $32.50 | N/A | Downgrades | 2 years ago |
Checkpoint Therapeutics IncCKPT | 3 | Strong Buy | $4.00 | N/A | Maintains | 2 years ago |
Ngm Biopharmaceuticals IncNGM | 4 | Strong Buy | $3.50 | N/A | Maintains | 2 years ago |
Scilex Holding CoSCLX | 1 | Strong Buy | $140.00 | N/A | Initiates Coverage On | 2 years ago |
Intercept Pharmaceuticals IncICPT | 8 | Hold | $19.00 | N/A | Downgrades | 2 years ago |
X4 Pharmaceuticals IncXFOR | 5 | Strong Buy | $90.00 | N/A | Maintains | 3 years ago |
Agenus IncAGEN | 1 | Strong Buy | $160.00 | N/A | Reiterates | 3 years ago |
Spectrum Pharmaceuticals IncSPPI | 4 | Hold | $1.00 | N/A | Downgrades | 3 years ago |
Gain Therapeutics IncGANX | 3 | Hold | $5.00 | N/A | Downgrades | 3 years ago |
Cassava Sciences IncSAVA | 3 | Strong Buy | $44.00 | N/A | Maintains | 3 years ago |
Fortress Biotech IncFBIO | 1 | Strong Buy | $90.00 | N/A | Maintains | 3 years ago |
Inmune Bio IncINMB | 2 | Hold | $7.00 | N/A | Downgrades | 3 years ago |
Tff Pharmaceuticals IncTFFP | 1 | Strong Buy | $450.00 | N/A | Maintains | 4 years ago |
Korro Bio IncKRRO | 1 | Strong Buy | $10.00 | N/A | Maintains | 4 years ago |
Allena Pharmaceuticals IncALNAQ | 3 | Hold | $0.50 | N/A | Downgrades | 4 years ago |
Scorpius Holdings IncSCPX | 1 | Strong Buy | $8.00 | N/A | Maintains | 4 years ago |
Seelos Therapeutics IncSEELQ | 2 | Strong Buy | $15,360.00 | N/A | Maintains | 4 years ago |
Mustang Bio IncMBIO | 3 | Strong Buy | $4,500.00 | N/A | Maintains | 4 years ago |
Biovie IncBIVI | 2 | Strong Buy | $2,700.00 | N/A | Maintains | 4 years ago |
Eloxx Pharmaceuticals IncELOX | 1 | Strong Buy | $200.00 | N/A | Initiates Coverage On | 4 years ago |
Arcturus Therapeutics Holdings IncARCT | 2 | Hold | $77.00 | N/A | Downgrades | 5 years ago |
Grace Therapeutics IncGRCE | 2 | Strong Buy | $96.00 | N/A | Upgrades | 5 years ago |
Galmed Pharmaceuticals LtdGLMD | 3 | Hold | $1,440.00 | N/A | Downgrades | 5 years ago |
Galectin Therapeutics IncGALT | 1 | Strong Buy | $4.00 | N/A | Maintains | 6 years ago |
IMV IncIMVIQ | 2 | Hold | $30.00 | N/A | Downgrades | 6 years ago |
Liberty Media CorpFWONK | 1 | Strong Buy | $39.00 | N/A | Maintains | 6 years ago |
Genfit SaGNFT | 1 | Strong Buy | $34.00 | N/A | Maintains | 6 years ago |
Arqule IncARQL | 1 | Hold | $20.00 | N/A | Downgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.